GlassScriptPhysician profile
Umesh S Mehta
NPI 1316903818
$2,132.67
in general payments reported to CMS, 2019-2025
11 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $389 · 2021: $211 · 2022: $143 · 2023: $345 · 2024: $384 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,056.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,055.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $421.54 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $349.37 | 2019-2025 | Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $310.72 | 2021-2025 | |
| Lundbeck LLC | $281.04 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $194.29 | 2019-2020 | |
| Indivior INC. | $192.43 | 2022-2024 | Perseris, Sublocade |
| Alkermes, INC. | $183.86 | 2019-2023 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $146.89 | 2019-2025 | Uzedy |
| Neurocrine Biosciences, INC. | $23.67 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.27 | 2020 | |
| Allergan, INC. | $12.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umesh Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.